GlassScriptPhysician profile
Jaina Morar Mehta
NPI 1841684487
$4,782.06
in general payments reported to CMS, 2019-2025
23 companies · $937 in 2025
The $937 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $335 · 2023: $993 · 2024: $2,221 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.93 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $725.52 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Abbvie INC. | $417.54 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $396.29 | 2022-2025 | Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $359.24 | 2021-2025 | |
| Janssen Biotech, INC. | $327.19 | 2021-2025 | Tremfya |
| Amgen INC. | $305.31 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $251.34 | 2022-2025 | Nemluvio |
| Ucb, INC. | $239.85 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $223.38 | 2022-2024 | Vtama |
| Lilly USA, LLC | $221.60 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $210.41 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $180.36 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $157.71 | 2021-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $149.39 | 2023-2025 | Sotyktu |
| Pfizer INC. | $140.80 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $137.10 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $104.97 | 2022-2024 | |
| Incyte Corporation | $76.00 | 2023-2025 | Opzelura |
| Smith+Nephew, INC. | $49.12 | 2023-2024 | Grafix Pl |
| Organon LLC | $35.59 | 2025 | Vtama |
| Almirall LLC | $30.32 | 2023 | Seysara |
| Verrica Pharmaceuticals INC. | $25.03 | 2024 | Ycanth |
| Convatec INC. | $18.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaina Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.